Orum Therapeutics reported preclinical data showing ORM‑1153 outperformed venetoclax in acute myeloid leukemia models, suggesting a potential efficacy advantage for Orum’s degrader‑antibody conjugate platform in AML. The company highlighted tumor reduction and mechanistic data in in‑vitro and in‑vivo systems. Although preclinical superiority does not guarantee clinical success, the results support further development and investor interest; Orum’s next steps will include IND‑enabling studies and strategic planning for first‑in‑human trials and potential combination strategies with standard AML regimens.